Markets
    Japan Stocks

    Rohto Pharmaceutical Falls 9% as First-Half Net Profit Drops 6.5% Despite Higher Sales

    The Hada Labo maker posted record sales and kept its full-year forecast, but net profit fell on a one-off dividend gain a year earlier and it cut its outlook for the Americas.

    Share on X LinkedIn WhatsApp
    The Umeda skyline in Osaka
    The Umeda district of Osaka, where Rohto is based Photo: Loggieloggie via Wikimedia Commons, CC0

    What to know

    • Rohto shares closed at 2,445.5 yen on Nov. 13, down 241 yen or 8.97%, after opening about 12.5% lower.
    • First-half net profit fell 6.5% to 16.5 billion yen as dividend income dropped to 818 million yen from 4.13 billion yen, even though sales rose 9.0% to a record 179.0 billion yen.
    • Rohto kept its full-year operating profit forecast at 45 billion yen but cut its Americas segment profit outlook to 300 million yen from 1.2 billion yen on lower U.S. eye drop shipments.

    TOKYO

    Shares of Rohto Pharmaceutical, the Japanese maker of Hada Labo skincare and Rohto eye drops, fell 8.97% on Friday after the company reported a 6.5% drop in first-half net profit. The company also trimmed its outlook for the Americas. The stock closed the Nov. 13 session at 2,445.5 yen, down 241 yen, according to Tokyo Stock Exchange data compiled by Kabutan.

    The selloff matters beyond Japan. Asia now produces more than a third of Rohto's sales, through brands such as Hada Labo and Acnes and through Eu Yan Sang International, a subsidiary that sells in Hong Kong, Singapore and Malaysia. The results showed that region growing fastest while the Americas segment slipped into a loss.

    A gap down, then a partial recovery

    Rohto opened at 2,352 yen, about 12.5% below Thursday's close of 2,686.5 yen, and touched a low of 2,329 yen before recovering some ground. Turnover reached about 4.75 million shares, more than three times the roughly 1.43 million traded on Thursday, the Kabutan data showed.

    MINKABU PRESS reported that investors appeared to treat the drop in bottom-line profit as a reason to sell. Fisco, the Tokyo financial news service, listed Rohto among Friday's notable decliners and pointed to the double-digit fall in first-half ordinary profit.

    Record sales, lower profit

    Rohto released its results for the six months to Sept. 30 after the market closed on Thursday, Nov. 12. Revenue rose 9.0% from a year earlier to 179.01 billion yen, a record for the half, and operating profit rose 8.5% to 20.95 billion yen, according to its filing.

    Lower down the income statement, the picture changed. Ordinary profit fell 11.2% to 21.85 billion yen, and net profit attributable to shareholders fell 6.5% to 16.50 billion yen. The company said the decline reflected a one-off dividend received in the previous year. Its income statement shows dividend income of 818 million yen in the latest half, against 4.13 billion yen a year earlier.

    A weaker yen helped the top line. The company's results presentation said the dollar averaged 159.75 yen in the half, up from 146.25 yen a year earlier, and that currency moves added about 8.33 billion yen to sales and about 889 million yen to operating profit.

    In Japan, sales rose 3.0% to 86.07 billion yen and segment profit rose 8.0% to 11.94 billion yen. Rohto said its Rohto V5 supplement, Hada Labo skincare, eye drops aimed at younger buyers and premium-priced eye drops sold well, and that a Hada Labo price increase in April, along with more in-house production, lowered its cost ratio. The presentation also said sunscreen sales struggled as competition intensified.

    Asia was the strongest region. Sales there rose 17.1% to 67.16 billion yen, and segment profit rose 12.4% to 8.03 billion yen, helped by Eu Yan Sang, China, Vietnam, Malaysia and Indonesia, the filing said. Profit in China fell even as sales rose sharply, because of higher advertising spending, according to the presentation.

    Eu Yan Sang itself had a strong half. Its sales rose 13.8% to 19.33 billion yen and its operating profit rose 19.1% to 1.63 billion yen, the presentation showed, with currency moves adding about 1.81 billion yen to sales. Its Malaysian business grew by double digits on strong Lunar New Year sales. Sales in Hong Kong fell in local currency terms but rose slightly once converted into yen, and Singapore sales dipped slightly in local currency, the company said.

    Europe, led by Poland's DAX Cosmetics, more than tripled its segment profit to 717 million yen.

    The Americas went the other way. Sales in the region edged up 2.3% to 10.34 billion yen, but the segment swung to an operating loss of 403 million yen from a profit of 428 million yen a year earlier. The company cited lower eye drop shipments in the United States and higher raw material and fuel costs. Eye care sales in the Americas fell 51.2% to 639 million yen.

    Forecast held, but the mix shifts

    Rohto kept its forecast for the year to March 2027 unchanged from Aug. 6: revenue of 372.3 billion yen, operating profit of 45.0 billion yen and net profit of 35.2 billion yen, all of which would be records. The company said first-half results were broadly in line with its plan.

    Under the unchanged total, it reshuffled its regional targets. It cut its Americas operating profit forecast to 300 million yen from 1.2 billion yen and its Americas sales forecast to 21.4 billion yen from 22.6 billion yen. It raised its operating profit outlook for Japan to 23.9 billion yen from 23.4 billion yen and for Asia to 17.6 billion yen from 17.3 billion yen. The presentation said Eu Yan Sang was running below the company's initial assumptions, while other Asian markets were doing better than expected.

    The first half delivered 46.6% of the full-year operating profit target and 46.9% of the net profit target. To hit the forecast, Rohto would need operating profit of about 24.05 billion yen in the October to March half, roughly 10% more than the 21.80 billion yen it earned in the same period a year earlier, based on figures in the filing. It now assumes 158 yen to the dollar for the full year.

    For background on how Japanese households are responding to higher prices, see our report on October consumer confidence.

    The company left its dividend plan at 50 yen a share for the year, split evenly between the interim and year-end payments, which would be its 23rd consecutive annual increase. It completed a 3 billion yen share buyback on Sept. 14. The 25-yen interim dividend is due to be paid on Dec. 8.

    Sources

    1. Rohto Pharmaceutical Co. (TDnet filing): 2027年3月期 第2四半期(中間期)決算短信〔日本基準〕(連結) (Nov. 12, 2026)
    2. Rohto Pharmaceutical Co. (TDnet filing): 2027年3月期 第2四半期(中間期) 決算説明会資料 (Nov. 13, 2026)
    3. MINKABU PRESS via Kabutan: ロートは大幅反落、前年同期の反動で4~9月期最終減益 (Nov. 13, 2026)
    4. Fisco via Kabutan: 前日に動いた銘柄 part2 森組、児玉化学、アイビーなど (Nov. 14, 2026)
    5. Kabutan (Tokyo Stock Exchange data): Rohto Pharmaceutical (4527) daily price history (Nov. 13, 2026)

    Capital Times Staff

    Capital Times newsroom, Hong Kong, Singapore and Jakarta

    Capital Times covers markets, business and economies across Asia.

    newsroom@capitaltimes.asia

    Our standards: Capital Times reports under the principles set out in our Editorial Standards and Ethics Policy. Spotted an error? Report it to our editors.

    Markets Data

    Hong Kong OpenShanghai OpenTokyo LunchSeoul OpenSingapore OpenJakarta OpenSydney OpenMumbai Closed